Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice

World Journal of Gastroenterology

Volumn 11, Issue 2, 2005, Pages 216-220

  Zhang, Zhong Lin ^a   Liu, Zhi Su ^a   Sun, Quan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Neoplasm metastasis; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; CARBOXYMETHYLCELLULOSE; CD34 ANTIGEN; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME;

EID: 12344321483     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i2.216     Document Type: Article

References (29)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-18
3. Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE. Clinical research on antiangiogenic therapy. Pharmacol Res 1998; 37: 1-16
4. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the world-wide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
5. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085
6. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7: 339-343
7. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978
8. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-466
9. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001; 92: 2364-2473
10. Govindarajan R. Irinotecan and thalidomide in metastatic colorectal cancer. Oncology 2000; 14(12 Suppl 13): 29-32
11. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2710-2717
12. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, Xue Q. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003; 129: 43-51
13. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8
14. Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001; 163: 191-200
15. Kotoh T, Dhar DK, Masunaga R, Tabara H, Tachibana M, Kubota H, Kohno H, Nagasue N. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999; 125: 536-544
16. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-651
17. Verheul HM, Panigrahy D, Yuan J, D'Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999; 79: 114-118
18. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812-817
19. Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O, Klausner JM. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996; 16: 3673-3677
20. Santos-Mendoza T, Favila-Castillo L, Oltra A, Tamariz J, Labarrios F, Estrada-Parra S, Estrada-Garcia L. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allergy Immunol 1996; 111: 13-17
21. Belo AV, Ferreira MA, Bosco AA, Machado RD, Andrade SP. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001; 25: 91-96
22. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000; 59: 1489-1499
23. Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ, Kojiro M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000; 7: 725-729
24. Shimamura T, Saito S, Morita K, Kitamura T, Morimoto M, Kiba T, Numata K, Tanaka K, Sekihara H. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15: 640-646
25. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with dinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001; 182: 298-304
26. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activty of thalidomide. BioDrugs 2001; 15: 681-703
27. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833
28. Raufman JP, Lamps LW. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C. Am J Gastroenterol 2001; 96: 3209-3211
29. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23: 319-321